Duquesne Family Office’s BioNTech BNTX Stock Holding History

Duquesne Family Office’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-38,800	Closed	-$4.83M	–	56
2023 Q1	$4.83M	Buy	+38,800	New	+$5.33M	0.21%	41
2020 Q3	–	Sell	-204,450	Closed	-$13.6M	–	64
2020 Q2	$13.6M	Buy	+204,450	New	+$10.2M	0.42%	45

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Duquesne Family Office's BNTX Position: Q2 2023 in Review

Duquesne Family Office sold out of BioNTech (BNTX) in Q2 2023, closing a stake of 38,800 shares — an estimated $4.83M sold.

Duquesne Family Office first reported a position in BNTX in Q2 2020 and held it in 2 quarters. The position peaked at $13.6M in Q2 2020. 253 funds tracked by Wall St. Rank hold BNTX as of Q2 2023.

Duquesne Family Office reported no remaining BioNTech position as of Q2 2023 after selling out during the quarter.
Duquesne Family Office sold 38,800 BioNTech shares in Q2 2023, an estimated $4.83M.
Duquesne Family Office first reported a position in BioNTech in Q2 2020 and held it in 2 quarters.
Duquesne Family Office's BioNTech position peaked at $13.6M in Q2 2020.
253 funds tracked by Wall St. Rank held BioNTech as of Q2 2023.

Based on Duquesne Family Office's 13F filing for Q2 2023, filed 14 Aug 2023.